Eli Lilly’s $1.4 trillion valuation is heavy with hope
LLY•Eli Lilly’s $1.4 trillion valuation reflects strong sales of Mounjaro and Zepbound and expectations for its drug pipeline. But generic competition, lower-priced pills and risks to experimental treatments could challenge forecasts built into the valuation.
1. Growth and pipeline
Eli Lilly sold more than $36 billion of Zepbound and Mounjaro last year, and analysts expect sales of the drugs to exceed $88 billion by 2030. Its experimental drug retatrutide produced average weight loss of 28.7% at the highest dose after 68 weeks, though nearly one in five participants on that dose stopped treatment because of side effects.
2. Competition and pricing
Novo Nordisk’s semaglutide drugs face expiration of their main US patent in 2031, and generic versions could put pressure on prices across the category. Oral weight-loss drugs, which typically cost about a third as much as injectables, could add to pricing pressure. Around 50% of GLP-1 users stop taking the medication after six months, while Lilly is testing related drugs that may be easier to tolerate.
3. Valuation depends on pipeline
Visible Alpha forecasts project Lilly’s sales will rise nearly 10% in the four years after its current GLP-1 sales begin to decline in 2031. Berenberg analysts estimate the net present value of Lilly’s drugs and existing pipeline at about $647 billion, implying the remaining $700 billion of its market value depends on greater success or sales than their forecast. Lilly trades at more than 13 times expected sales, compared with four times for Novo Nordisk and less than three times for the average pharmaceutical company.



